Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy

Qianqian Guo; Xiaoxuan Xu; Xiaojiang Lai; Jialin Duan; Dan Yan; Dangge Wang

doi:10.1002/EXP.20230115

Exploration ›› 2025, Vol. 5 ›› Issue (2) : 20230115 DOI: 10.1002/EXP.20230115

RESEARCH ARTICLE

Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy

Author information +

History +

PDF

Abstract

Cancer vaccines are promising to treat malignancy by delivering antigens and adjuvants to elicit host immunity. Beyond aluminum adjuvants, liposomes show efficient adjuvant effects through regulating the accumulation, internalization and release of payloads. However, it remains unknown that whether the liposome will perform intrinsic adjuvant effects in the absence of antigens and adjuvants. Herein, a library of antigen/adjuvant-free liposomes with variable surface charges has been developed and it has been found that highly anionic liposomes show promising adjuvant effects for boosting immune responses. The anionic liposome mobilizes the MyD88 pathways of dendritic cells (DCs) to activate T helper cells and CD8⁺ T cells. The anionic liposomes enhance host immunity by regulating the population of Th1, Th2 and regulatory T cells (Tregs), and boost adaptive CD8⁺ T cells in lymphoid organs with good biosafety. It shows the most efficient protection against MC38 colorectal cancer in mice after a parallel injection of antigens and anionic liposomes. Overall, this study reveals that the surface charge of liposome affects its adjuvant efficiency and provides an anionic nanosized adjuvant formulation for enhancing immunization.

Keywords

adjuvants / cancer vaccine / immunotherapy / liposome / surface charge

Cite this article

Download citation ▾

Qianqian Guo, Xiaoxuan Xu, Xiaojiang Lai, Jialin Duan, Dan Yan, Dangge Wang. Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy. Exploration, 2025, 5(2): 20230115 DOI:10.1002/EXP.20230115

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	M. J. Lin, J. Svensson-Arvelund, G. S. Lubitz, A. Marabelle, I. Melero, B. D. Brown, J. D. Brody Nat. Cancer 2022, 3, 911.

[2]	F. Lang, B. Schrörs, M. Löwer, Ö. Türeci, U. Sahin, Nat Rev. Drug Discovery 2022, 21, 261.

[3]

A. Khattak, J. S. Weber, T. Meniawy, M. H. Taylor, G. Ansstas, K. B. Kim, M. McKean, G. V. Long, R. J. Sullivan, M. B. Faries, T. Tran, C. L. Cowey, T. M. Medina, J. M. Segar, V. Atkinson, G. T. Gibney, J. J. Luke, E. I. Buchbinder, R. S. Meehan, M. S. Carlino, b. M. A. Grp, J. Clin. Oncol. 2023, 41, LBA9503.

[4]	W. J. Lee, M. Suresh, Front. Immunol. 2022, 13, 940047.

[5]	B. Pulendran, P. S. Arunachalam, D. T. O'Hagan, Nat. Rev. Drug Discovery 2021, 20, 454.

[6]	T. Zhao, Y. Cai, Y. Jiang, X. He, Y. Wei, Y. Yu, X. Tian, Signal Transduction Targeted Ther. 2023, 8, 283.

[7]	a) A. M. Vargason, A. C. Anselmo, S. Mitragotri, Nat. Biomed. Eng. 2021, 5, 951; b) A. Ukidve, K. Cu, M. Goetz, P. Angsantikul, A. Curreri, E. E. L. Tanner, J. Lahann, S. Mitragotri, Adv. Mater. 2020, 32, 2002990.

[8]	A. Mukherjee, B. Bisht, S. Dutta, M. K. Paul, Acta Pharmacol. Sin. 2022, 43, 2759.

[9]	K. L. Swingle, A. G. Hamilton, M. J. Mitchell, Trends Mol. Med. 2021, 27, 616.

[10]	N. Wang, M. Chen, T. Wang, J. Controlled Release 2019, 303, 130.

[11]	a) Y. Xia, S. Fu, Q. Ma, Y. Liu, N. Zhang, Nano-Micro Lett. 2023, 15, 145; b) K. J. Hassett, J. Higgins, A. Woods, B. Levy, Y. Xia, C. J. Hsiao, E. Acosta, Ö. Almarsson, M. J. Moore, L. A. Brito, J. Controlled Release 2021, 335, 237.

[12]	G. Zhu, Y.-G. Yang, T. Sun, Biomater. Sci. 2022, 10, 1408.

[13]

a) A. W. Li, M. C. Sobral, S. Badrinath, Y. Choi, A. Graveline, A. G. Stafford, J. C. Weaver, M. O. Dellacherie, T. Y. Shih, O. A. Ali, J. Kim, K. W. Wucherpfennig, D. J. Mooney, Nat. Mater. 2018, 17, 528; b) K. Luisi, K. M. Morabito, K. E. Burgomaster, M. Sharma, W. P. Kong, B. M. Foreman, S. Patel, B. Fisher, M. A. Aleshnick, J. Laliberte, M. Wallace, T. J. Ruckwardt, D. N. Gordon, C. Linton, N. Ruggiero, J. L. Cohen, R. Johnson, K. Aggarwal, S. Y. Ko, E. S. Yang, R. S. Pelc, K. A. Dowd, D. O'Hagan, J. Ulmer, S. Mossman, A. Sambor, E. Lepine, J. R. Mascola, T. C. Pierson, B. S. Graham, D. Yu, Sci. Adv. 2020, 6, aba5068.

[14]	a) R. Zhang, L. Tang, Y. Tian, X. Ji, Q. Hu, B. Zhou, Z. Ding, H. Xu, L. Yang, J. Controlled Release 2020, 328, 210; b) J. Tan, B. Ding, B. Teng, P. A. Ma, J. Lin, Adv. Funct. Mater. 2022, 32, 2111670; c) E. Yuba, Y. Kado, N. Kasho, A. Harada, J. Controlled Release 2023, 362, 767.

[15]	M. M. T. van Leent, B. Priem, D. P. Schrijver, A. de Dreu, S. R. J. Hofstraat, R. Zwolsman, T. J. Beldman, M. G. Netea, W. J. M. Mulder, Nat. Rev. Mater. 2022, 7, 465.

[16]	M. Z. Ahmad, J. Ahmad, M. Y. Alasmary, B. A. Abdel-Wahab, M. H. Warsi, A. Haque, P. Chaubey, Immunotherapy 2021, 13, 491.

[17]	S. Zhou, Y. Luo, J. F. Lovell, Expert Rev. Vaccines 2023, 22, 1022.

[18]	a) Y. Zhang, N. V. Hudson-Smith, S. D. Frand, M. S. Cahill, L. S. Davis, Z. V. Feng, C. L. Haynes, R. J. Hamers, J. Am. Chem. Soc. 2020, 142, 10814; b) A. Bernier, T. Tobias, H. Nguyen, S. Kumar, B. Tuga, Y. Imtiaz, C. W. Smith, R. Sunasee, K. Ckless, Nanomaterials 2021, 11, 2072.